Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 416Thoracic 5Gastrointestinal 2Lymphoid 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 5744Lung Neoplasms 3716Small Cell Lung Carcinoma 1017Breast Neoplasms 667Neoplasms 616Colorectal Neoplasms 556Melanoma 479Ovarian Neoplasms 434Neoplasm Metastasis 431Pancreatic Neoplasms 386Stomach Neoplasms 332Carcinoma, Renal Cell 311Adenocarcinoma of Lung 308Squamous Cell Carcinoma of Head and Neck 304Head and Neck Neoplasms 293Prostatic Neoplasms 284Mesothelioma, Malignant 281Esophageal Neoplasms 265Mesothelioma 244Colonic Neoplasms 225Brain Neoplasms 216Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 209Uterine Cervical Neoplasms 207Endometrial Neoplasms 174Sarcoma 171Carcinoma, Hepatocellular 158NSCLC 134Kidney Neoplasms 127Carcinoma 127

Interventions

sotorasib 1pembrolizumab 1osimertinib 1ensartinib 1binimetinib 1Nivolumab 1LY-2157299 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Solid Tumor × Thoracic × Clear all
NCT06816108 2026-01-12

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Ono Pharmaceutical Co., Ltd.

Phase 1 Recruiting
60 enrolled
Other solid neoplasmThoracic

Solid Tumor

NCT04720976 2025-04-11

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

Allist Pharmaceuticals, Inc.

Phase 1/2 Completed
58 enrolled
Other solid neoplasmThoracic

Solid Tumor

NCT03861156 2024-04-09

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

InventisBio Co., Ltd

Phase 2 Completed
290 enrolled
Other solid neoplasmThoracic

Solid Tumor

NCT02959619 2023-08-21

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Betta Pharmaceuticals Co., Ltd.

Phase 1 Completed
48 enrolled
Other solid neoplasmThoracic

Solid Tumor

NCT02423343 2021-09-09

A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma

Eli Lilly and Company

Phase 1/2 Completed
41 enrolled 21 charts
GastrointestinalOther solid neoplasmThoracic

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡